Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of measles-rubella vaccine microneedle patch formulations manufactured by Micron Biomedical
PACTR202610853872997Phase 2Not yet recruiting
- Sponsor
- PATH
- Start
- Mar 2027
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of measles vaccine, live attenuated + rubella vaccine, live attenuated and measles and rubella vaccine in measles and rubella (4 arms), sponsored by PATH. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
measles vaccine, live attenuated + rubella vaccine, live attenuatedmeasles and rubella vaccine
03
Conditions
measlesrubella
Beyond the preview
Go deeper on PACTR202610853872997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610853872997.